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prostate cancer. The objective of this sub-study is to 
evaluate infraction motion, using cine MRI, and the 
dosimetric impact when using a rectal immobilisation device 
(RID). 
 
Material and Methods: The initial 10 patients recruited 
underwent planning CT and MRI, with and without a RID. Cine 
MRI images were captured using an interleaved T2 HASTE 
sequence in sagittal and axial planes with a temporal 
resolution of 5.4 seconds acquired over 4 minutes, the 
average time for a single SBRT VMAT fraction. Points of 
interest (POI) were outlined by a single investigator and a 
validated tracking algorithm measured displacement of these 
points over the 4 minutes in the anterior – posterior, superior 
– inferior and left – right directions (Figure 1). 
 
 
 
Planning CT and MRI scans were fused and contoured by a 
single investigator. They were planned using a VMAT 
technique to 19Gy in 2 fractions by a single investigator. The 
planning priority set for the non – RID plan was to match the 
coverage achieved in the RID plan. Dose Volume Histogram 
results of both plans were analysed. 
 
Results: There was an overall trend for increasing POI 
displacement in all directions as time progressed when no RID 
was insitu. POI remained comparatively stable with the RID.  
In the sagittal plane, the RID resulted in statistically 
significant improvement in the range of anterior - posterior 
displacement over the entire 4 minutes of the inferior 
anterior and posterior rectal wall (both p <0.001), mid 
anterior and posterior rectal wall (both p = 0.007), anterior 
prostate (p =0.019), prostate apex (p = 0.003) and prostate 
base (p=0.011).  
The RID also resulted in improvement in range of superior - 
inferior displacement of the inferior posterior rectal wall (p = 
0.002), mid anterior rectal wall (p = 0.043) and posterior 
rectal wall (p = 0.023).  
In the axial plane, the RID resulted in statistically significant 
improvement in the range of anterior - posterior 
displacement of the anterior rectal wall (p =0.008) and 
posterior prostate (p=0.011).  
For all these points, the RID approximately halved the range 
of displacements, with some points moving over 2mm when 
no RID was insitu. 
Dosimetrically, the use of a RID significantly reduced rectal 
V16 (0.27cc vs 1.71cc; p < 0.001), V14 (1.12cc vs 2.32cc; p 
=0.02) and Dmax (15.72Gy vs 18.90Gy; p < 0.001), as well as 
percentage of posterior rectal wall receiving 8.5Gy (7.38% vs 
12.20%; p = 0.003). There was no statistically significant 
difference between bladder or urethral Dmax, CTV D98 or 
conformity index between both plans. 
 
Conclusion: The rectal immobilisation device used in 
stereotactic prostate radiotherapy leads to reduced 
intrafraction motion of the prostate and rectum, with 
increasing improvement with time. It also results in 
significant improvement in rectal wall dosimetry. 
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Purpose or Objective: The purpose of this study was to 
analyze the modulation indexes proposed in the literature for 
predicting interplay effects in lung SABR treatments 
 
Material and Methods: 23 SABR plans (4 arcs of 200°-220° for 
6MV and 2 arcs for 10 MV FFF) calculated on Eclipse V10.1 
(Varian) were analyzed with the Quasar respiratory phantom 
(Modus Medical Devices) by comparing dose distributions on 
EBT3 radiochromic film. Static and dynamic irradiation at 0.5 
cm amplitude (1 cm peak-to-peak) and 12 breaths per minute 
(BPM) was used. 18 plans were irradiated in a Silouette LINAC 
with 6 MV and 5 on a TrueBeam (Varian) LINAC with 6 MV 
FFF. The acceptance criteria was set to be < 5% of points 
with γ( 3%,3mm )>1 on the comparison between static and 
dynamic dose distributions. A threshold of 90% was fixed 
since the aim was to study the influence of the modulation 
on the ITV. The modulation indexes analyzed were: The 
Modulation Complexity Score (MCS)-McNiven 2010; the 
Modulation Index Total (MIt)- Park 2014 which introduces 
speed and MLC acceleration and finally the Aperture 
Irregularity (AI) -Du 2014 which analyzes the non-circularity 
of the MLC apertures. A Matlab (Mathworks) program was 
developed to calculate them. Finally, the PUMA method, 
which is based on splitting arcs in the TPS and modeling 
movements by changing their isocenter positions, was also 
used. Possible linear correlation between these indexes and 
radiochromic films was analyzed and a statistical analysis 
performed. 
 
Results: Modulation indexes are shown in Table 1. A 
statistical analysis of the goodness of fit was done; which 
found only significant linear correlation (p < 0.0001) between 
film-PUMA, film-MIt and also between PUMA-MIt A positive 
plan is considered to be a plan suitable for treatment when 
evaluating the interplay effect. A value of 0.6 for the MIt 
index is proposed as the upper limit. This value was selected 
in order to minimize the number of false negative plans. MIt 
and PUMA have the same specificity (100%) since both 
detected all of the failing plans. However, PUMA has a 
greater sensitivity (95% vs 85%). 
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Conclusion: Most of the modulation indexes proposed in the 
literature are related to the robustness and modulation of a 
plan. However, none of them has been conceived to 
appropriately predict the interplay effect in lung SABR. MIt 
has been found to be the only published index capable of 
detecting failing plans. MIt and PUMA have the same 
specificity since both detected all of the failing plans. 
However, PUMA has a greater accuracy and sensitivity. 
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Purpose or Objective: The objective of this HERO study was 
to assess the number of new cancer patients that will require 
at least one course of radiotherapy by 2025 compared to the 
2012 figure, by tumor site and European country. 
 
Material and Methods: European cancer incidence data by 
tumor site and country for 2012 and 2025 was extracted from 
the GLOBOCAN database. The projection of the number of 
new cases took into account demographic factors (age and 
size of the population). Population based stages at diagnosis 
were taken from four European countries. Incidence and 
stage data were introduced in the Australian Collaboration 
for Cancer Outcomes Research and Evaluation (CCORE) 
model,  thus producing an evidence-based proportion of 
incident cases with an indication for radiotherapy, the 
Optimal Utilization Proportion (OUP).  From these values, the 
number of cases that would require radiotherapy on an 
annual basis in each country was calculated. 
 
Results: Among the difference tumor sites, the highest 
expected relative increase by 2025 in treatment courses was 
prostate cancer (24%) while lymphoma (13%), head and neck 
(12%) and breast cancer (10%) were below the average. 
Cervical (1%) and testicular cancer (-6%) were the sites with 
the lowest expected increase. Based on the projected cancer 
distributions in 2025, a 16% expected increase in the number 
of radiotherapy treatment courses was estimated. This 
increase varied across European countries from less than 5% 
(Bulgaria, Latvia, Lithuania, Ukraine, Belarus, Estonia, 
Moldova) to more than 30% (Switzerland, Luxembourg, Malta, 
Iceland, Ireland, Albania, Cyprus). 
 
Conclusion: This HERO study showed that the need for 
radiotherapy in Europe is, on average, expected to increase 
with 16% over the next decade. The expected changes varied 
considerably between countries (range 0-38%). With the 
already existing disparity in radiotherapy resources in mind, 
the data provided here should act as a leverage point to raise 
awareness among European health policy makers of the need 
for investment in radiotherapy.  
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Purpose or Objective: Current clinical trials and studies are 
identifying hypofractionation as a viable treatment option 
when compared with current fractionation regimens. Our 
work estimates the reduction in the number of fractions 
prescribed and the potential effect on the overall demand for 
radiotherapy across the whole of England. With the evidence 
based estimates of demand for radiotherapy currently 
outstripping the supply capacity in England, this potential 
reduction in fraction demand needs to be calculated to assess 
the potential effects for radiotherapy service and 
infrastructure planning. 
 
Material and Methods: The Malthus Program, a tool for 
modelling radiotherapy demand, was used to calculate the 
potential effect of three hypofractionation studies/trials for 
the population of England. Well-published and potential 
clinical indications for hypofractionation have been modelled 
for prostate cancer, non-small cell lung cancer (NSCLC) and 
breast cancer. The hypofractionation indications for 
radiotherapy were mapped into the original Malthus clinical 
decision trees and simulations completed to study the effects 
of hypofractionation on demand. 
 
Results: If the CHHiP prostate trial achieves universal uptake 
throughout England then it has the potential to reduced 
radiotherapy demand by 3,500 fractions per million 
population (#pmp). SBRT for medically inoperable (or refusal 
of surgery) for stage 1 and stage 2 NSCLC has the potential to 
reduce the demand by a further 700 #pmp. The FAST-Forward 
trial, using 5# instead of 15# for T1-3 N0-1 M0 breast cancer 
